These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 21328522)

  • 1. Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group.
    Naranjo A; Parisi MT; Shulkin BL; London WB; Matthay KK; Kreissman SG; Yanik GA
    Pediatr Blood Cancer; 2011 Jul; 56(7):1041-5. PubMed ID: 21328522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of catecholamine metabolites, mIBG scan, and bone marrow cytology as response markers in stage 4 neuroblastoma.
    Hero B; Hunneman DH; Gahr M; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):220-3. PubMed ID: 11464889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group.
    Yanik GA; Parisi MT; Shulkin BL; Naranjo A; Kreissman SG; London WB; Villablanca JG; Maris JM; Park JR; Cohn SL; McGrady P; Matthay KK
    J Nucl Med; 2013 Apr; 54(4):541-8. PubMed ID: 23440556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma.
    Matthay KK; Edeline V; Lumbroso J; Tanguy ML; Asselain B; Zucker JM; Valteau-Couanet D; Hartmann O; Michon J
    J Clin Oncol; 2003 Jul; 21(13):2486-91. PubMed ID: 12829667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma.
    Mazloom A; Louis CU; Nuchtern J; Kim E; Russell H; Allen-Rhoades W; Krance R; Paulino AC
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):858-62. PubMed ID: 25245583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of advanced neuroblastoma in children over 1 year of age: the critical role of ¹³¹I-metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen.
    Mastrangelo S; Rufini V; Ruggiero A; Di Giannatale A; Riccardi R
    Pediatr Blood Cancer; 2011 Jul; 56(7):1032-40. PubMed ID: 21344615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scintigraphic response by 123I-metaiodobenzylguanidine scan correlates with event-free survival in high-risk neuroblastoma.
    Katzenstein HM; Cohn SL; Shore RM; Bardo DM; Haut PR; Olszewski M; Schmoldt J; Liu D; Rademaker AW; Kletzel M
    J Clin Oncol; 2004 Oct; 22(19):3909-15. PubMed ID: 15459212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study.
    Decarolis B; Schneider C; Hero B; Simon T; Volland R; Roels F; Dietlein M; Berthold F; Schmidt M
    J Clin Oncol; 2013 Mar; 31(7):944-51. PubMed ID: 23341514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy.
    Kushner BH; Yeh SD; Kramer K; Larson SM; Cheung NK
    J Clin Oncol; 2003 Mar; 21(6):1082-6. PubMed ID: 12637474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97.
    Schmidt M; Simon T; Hero B; Schicha H; Berthold F
    Eur J Cancer; 2008 Jul; 44(11):1552-8. PubMed ID: 18424129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1.
    Yanik GA; Parisi MT; Naranjo A; Nadel H; Gelfand MJ; Park JR; Ladenstein RL; Poetschger U; Boubaker A; Valteau-Couanet D; Lambert B; Castellani MR; Bar-Sever Z; Oudoux A; Kaminska A; Kreissman SG; Shulkin BL; Matthay KK
    J Nucl Med; 2018 Mar; 59(3):502-508. PubMed ID: 28887399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system.
    Suc A; Lumbroso J; Rubie H; Hattchouel JM; Boneu A; Rodary C; Robert A; Hartmann O
    Cancer; 1996 Feb; 77(4):805-11. PubMed ID: 8616776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent positive metaiodobenzylguanidine scans after autologous peripheral blood stem cell transplantation may indicate maturation of stage 4 neuroblastoma.
    Okamoto Y; Kodama Y; Nishikawa T; Rindiarti A; Tanabe T; Nakagawa S; Yoshioka T; Takumi K; Kaji T; Kawano Y
    Pediatr Hematol Oncol; 2017 Apr; 34(3):157-164. PubMed ID: 28976242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
    DuBois SG; Mody R; Naranjo A; Van Ryn C; Russ D; Oldridge D; Kreissman S; Baker DL; Parisi M; Shulkin BL; Bai H; Diskin SJ; Batra V; Maris JM; Park JR; Matthay KK; Yanik G
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28383813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporation of high-dose
    Lee JW; Lee S; Cho HW; Ma Y; Yoo KH; Sung KW; Koo HH; Cho EJ; Lee SK; Lim DH
    J Hematol Oncol; 2017 May; 10(1):108. PubMed ID: 28511709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of diagnostic and end-of-induction Curie scores with tandem high-dose chemotherapy and autologous transplants for metastatic high-risk neuroblastoma: A report from the Children's Oncology Group.
    Streby KA; Parisi MT; Shulkin BL; LaBarre B; Bagatell R; Diller L; Grupp SA; Matthay KK; Voss SD; Yu AL; London WB; Park JR; Yanik GA; Naranjo A
    Pediatr Blood Cancer; 2023 Aug; 70(8):e30418. PubMed ID: 37199022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response-adapted consolidation therapy strategy for patients with metastatic high-risk neuroblastoma: Results of the SMC NB-2014 study.
    Seo ES; Lee JW; Cho HW; Ju HY; Cho YS; Lee S; Moon SH; Yoo KH; Lim DH; Sung KW
    Pediatr Blood Cancer; 2024 Sep; 71(9):e31173. PubMed ID: 38965702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 131I-MIBG followed by consolidation with busulfan, melphalan and autologous stem cell transplantation for refractory neuroblastoma.
    French S; DuBois SG; Horn B; Granger M; Hawkins R; Pass A; Plummer E; Matthay K
    Pediatr Blood Cancer; 2013 May; 60(5):879-84. PubMed ID: 23024113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.
    Ladenstein R; Lambert B; Pötschger U; Castellani MR; Lewington V; Bar-Sever Z; Oudoux A; Śliwińska A; Taborska K; Biassoni L; Yanik GA; Naranjo A; Parisi MT; Shulkin BL; Nadel H; Gelfand MJ; Matthay KK; Park JR; Kreissman SG; Valteau-Couanet D; Boubaker A
    Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):292-305. PubMed ID: 28940046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metaiodobenzylguanidine assessment of metastatic neuroblastoma: observer dependency and chemosensitivity evaluation. The SFOP Group.
    Frappaz D; Bonneu A; Chauvot P; Edeline V; Giammarile F; Siles S; Wioland M; Gomez F
    Med Pediatr Oncol; 2000 Apr; 34(4):237-41. PubMed ID: 10742058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.